Trial Title:
ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
NCT ID:
NCT05653063
Condition:
Cancer of Prostate
Cancer Head Neck
Cancer Cervix
Conditions: Official terms:
Prostatic Neoplasms
Head and Neck Neoplasms
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
A web-based artificial intelligence (AI) auto-planning tool
Description:
The CT scan taken at the time of treatment planning is uploaded to a web server called
the Radiotherapy planning assistant which automates the contouring of target organs and
areas of high-risk disease as well as defining the size, shape and number of radiotherapy
beams to treat the cancer. The final plan is downloaded to the local treatment planning
system where the doses are recalculated and clinical peer review is undertaken before the
plan can be used clinically.
In this study patients will not be treated with the AI tool but the manual plan created
by the local teams.
Summary:
The aim of this study is to look at whether an Artificial Intelligence (AI) based
computer program can automate two components of the radiotherapy treatment pathway to a
sufficient quality standard to enable its routine clinical use. The two components
include the delineation (outlining) of anatomical areas that are at risk of tumour spread
and at risk of radiation damage, and the definition of the position, size and shape of
the radiation beams.
The AI-based computer programs have been developed to perform tasks that would normally
require direct human involvement by oncologists and medical physicists. Proposed
advantages include improved treatment accuracy, as well as a reduction in the time (from
weeks to minutes) and human resources needed to deliver radiotherapy, which this study
will test.
Criteria for eligibility:
Study pop:
Patients eligible for radiotherapy for head and neck, cervical or prostate cancer.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Consecutive patients with histologically confirmed head and neck cancers of the
oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given
consent for radical radiotherapy.
2. Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB
including pelvic node positive) that have given consent for radical radiotherapy.
3. Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0)
that have given consent for radical radiotherapy.
4. Mental capacity to understand and consent to participate in the study.
5. Patients aged ≥18years.
Exclusion Criteria:
1. Patients requiring radiotherapy after curative surgery or surgery that is intended
to remove as much of the tumour as possible.
2. Patients receiving palliative radiotherapy
3. Patients aged < 18years.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Tata Medical Centre
Address:
City:
Kolkata
Country:
India
Status:
Recruiting
Contact:
Last name:
Dr Mallick
Facility:
Name:
Tata Memorial Hospital
Address:
City:
Mumbai
Country:
India
Status:
Recruiting
Contact:
Last name:
Dr Ghosh-Laskar
Facility:
Name:
King Hussein Cancer Center
Address:
City:
Amman
Country:
Jordan
Status:
Recruiting
Contact:
Last name:
Dr Mohamad
Facility:
Name:
University of Malaya Medical Center
Address:
City:
Kuala Lumpur
Country:
Malaysia
Status:
Recruiting
Contact:
Last name:
Dr Malik
Facility:
Name:
Groote Schuur Hospital
Address:
City:
Cape Town
Country:
South Africa
Status:
Recruiting
Contact:
Last name:
Prof Parkes
Facility:
Name:
Tygerberg Hospital
Address:
City:
Stellenbosch
Country:
South Africa
Status:
Not yet recruiting
Contact:
Last name:
Dr Trauernicht
Start date:
December 7, 2023
Completion date:
September 1, 2026
Lead sponsor:
Agency:
University College, London
Agency class:
Other
Collaborator:
Agency:
National Institutes of Health (NIH)
Agency class:
NIH
Collaborator:
Agency:
Rising Tide Foundation
Agency class:
Other
Collaborator:
Agency:
Medical Research Council
Agency class:
Other
Collaborator:
Agency:
Tata Memorial Hospital
Agency class:
Other
Collaborator:
Agency:
Tata Memorial Centre
Agency class:
Other
Collaborator:
Agency:
University of Stellenbosch
Agency class:
Other
Collaborator:
Agency:
King Hussein Cancer Center
Agency class:
Other
Collaborator:
Agency:
University of Malaya
Agency class:
Other
Collaborator:
Agency:
University Ghent
Agency class:
Other
Collaborator:
Agency:
M.D. Anderson Cancer Center
Agency class:
Other
Collaborator:
Agency:
Mount Vernon Cancer Centre at Mount Vernon Hospital
Agency class:
Other
Collaborator:
Agency:
University of Cape Town
Agency class:
Other
Collaborator:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
University College, London
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05653063
